Literature DB >> 17876853

Withdrawal of visual feedback improves micrographia in Parkinson's disease.

William G Ondo1, Pankaj Satija.   

Abstract

Micrographia is a common, often presenting feature of Parkinson's disease. We assessed a simple writing paradigm in 40 PD patients "off" medications, 40 different PD patients "on" medications, and 64 age- and sex-matched controls. Patients wrote "Today is a nice day" with both eyes open and eyes closed to assess the effects of visual withdrawal (eyes closure). The order (eyes open vs. eyes closed) was alternated. In the "off" medicine group, eye closure increased the writing length by 14.0 +/- 10.1% (P < 0.05) from a mean of 69.1 to 77.7 mm [range -14% to +73%]. The percentage increase was larger in the 20 subjects with the smallest baseline writing size (worse micrographia), compared to the 20 with relatively larger writing (19.5% vs. 7.9%, P < 0.05). Neither the "on" medicine group, nor the control group changed. Simple eye closure significantly increased writing size in "off" PD patients to a similar or greater amount as levodopa. This data suggests that micrographia is not a pure motor hypokinetic feature but is affected by PD similar to other superlearned tasks such as walking. Furthermore, some patients have adapted this simple eye closing strategy when writing, especially signatures. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17876853     DOI: 10.1002/mds.21733

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  An investigation of two interventions for micrographia in individuals with Parkinson's disease.

Authors:  M S Bryant; D H Rintala; E C Lai; E J Protas
Journal:  Clin Rehabil       Date:  2010-06-16       Impact factor: 3.477

2.  Handwriting as an objective tool for Parkinson's disease diagnosis.

Authors:  Sara Rosenblum; Margalit Samuel; Sharon Zlotnik; Ilana Erikh; Ilana Schlesinger
Journal:  J Neurol       Date:  2013-06-16       Impact factor: 4.849

3.  Micrographia and related deficits in Parkinson's disease: a cross-sectional study.

Authors:  Aparna Wagle Shukla; Songthip Ounpraseuth; Michael S Okun; Vickie Gray; John Schwankhaus; Walter Steven Metzer
Journal:  BMJ Open       Date:  2012-06-25       Impact factor: 2.692

4.  The Effect of Visual Feedback on Writing Size in Parkinson's Disease.

Authors:  Adriaan R E Potgieser; Elizabeth Roosma; Martijn Beudel; Bauke M de Jong
Journal:  Parkinsons Dis       Date:  2015-06-17

5.  Standardized handwriting to assess bradykinesia, micrographia and tremor in Parkinson's disease.

Authors:  Esther J Smits; Antti J Tolonen; Luc Cluitmans; Mark van Gils; Bernard A Conway; Rutger C Zietsma; Klaus L Leenders; Natasha M Maurits
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

6.  Visuomotor Dissociation in Cerebral Scaling of Size.

Authors:  Adriaan R E Potgieser; Bauke M de Jong
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

7.  Improvement in upper-limb UPDRS motor scores following fast-paced arm exercise: A pilot study.

Authors:  Shelly Levy-Tzedek; Dan Arbelle; Dan Forman; Yair Zlotnik
Journal:  Restor Neurol Neurosci       Date:  2018       Impact factor: 2.406

8.  Neural substrates underlying progressive micrographia in Parkinson's disease.

Authors:  Shigenori Kanno; Mayumi Shinohara; Kasumi Kanno; Yukihiro Gomi; Makoto Uchiyama; Yoshiyuki Nishio; Toru Baba; Yoshiyuki Hosokai; Atsushi Takeda; Hiroshi Fukuda; Etsuro Mori; Kyoko Suzuki
Journal:  Brain Behav       Date:  2020-06-18       Impact factor: 2.708

Review 9.  Handwriting Analysis in Parkinson's Disease: Current Status and Future Directions.

Authors:  Mathew Thomas; Abhishek Lenka; Pramod Kumar Pal
Journal:  Mov Disord Clin Pract       Date:  2017-11-01

10.  Patients' Self-Report and Handwriting Performance Features as Indicators for Suspected Mild Cognitive Impairment in Parkinson's Disease.

Authors:  Sara Rosenblum; Sonya Meyer; Ariella Richardson; Sharon Hassin-Baer
Journal:  Sensors (Basel)       Date:  2022-01-12       Impact factor: 3.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.